logo

Clinical Trial Results

Share

Novartis (NVS) announced positive results from the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) in combination with fulvestrant. The trial evaluated the efficacy and safety of alpelisib in postmenopausal women with PIK3CA mutated hormone-receptor...

Merrimack Pharmaceuticals, Inc. (MACK) announced the termination of the SHERLOC study, the company's randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer. The company said the the data demonstrated...

pharma-011918_18oct18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharma-012218_18oct18.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-010518_17oct18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharma-020818_17oct18.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-012317_16oct18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharma-aug-7_16oct18.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-011818_15oct18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharma-010617_15oct18.jpg The following are some of today's top gainers in the pharma/biotech sector.

Genentech, a member of the Roche Group (RHHBY), announced Monday that the Phase III KATHERINE study with Kadcyla in treatment of HER2-Positive early breast cancer or EBC met its primary endpoint. The KATHERINE trial investigated a population of people with HER2-positive EBC who did not achieve a pathological...

pharma-012418_11oct18.jpg The following are some of today's top gainers in the pharma/biotech sector.

Theravance Biopharma, Inc. (TBPH) and Mylan N.V. (MYL) said Thursday that positive new data from multiple studies of Yupelri, or revefenacin inhalation solution were presented at the 2018 CHEST annual meeting, held in San Antonio, Texas from October 6 to 10, 2018. Yupelri is an investigational long-acting...

Novartis (NVS) said that it will present 33 scientific abstracts at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS being held October 10-12, 2018 in Berlin, Germany. The presentations highlight the company's efforts to advance the understanding...

pharma-011017_09oct18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

Follow RTT